Obesity may spur DNA damage in the breast tissue of women who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in this already high-risk group, according to new multi-institutional translational research led by Weill Cornell Medicine scientists.

The study, published in the Science Translational Medicine, suggests that weight management and medications that impact metabolic health may be an important part of preventive care for women with these genetic mutations, although further research is needed.

Obesity and poor metabolic health are known breast cancer risk factors in the general population, “but whether these modifiable risk factors contribute to breast cancer development in BRCA mutation carriers has been largely unknown,” said senior study author Dr. Kristy A. Brown, the Emilie Lippmann and Janice Jacobs McCarthy Research Scholar in Breast Cancer and an associate professor of biochemistry in medicine at Weill Cornell Medicine.

Prior findings from epidemiological studies of the impact of body weight on breast cancer development in BRCA mutation carriers are unclear, said the paper’s first author Dr. Priya Bhardwaj, who was a doctoral candidate in the Weill Cornell Graduate School of Medical Sciences when the current research was being conducted.

“Our research provides clinicians with mechanistic evidence of the possible benefits of intervening on the metabolic side of the breast cancer disease process,” she said.

The researchers analysed noncancerous breast tissue samples from patients with either BRCA1 or BRCA2 mutations who had undergone mastectomy. The study population included women who had a body mass index (BMI) in the lower range of below 25 kg/m2 and those with a BMI of 25 or higher, categorised as overweight or obese.

Using immunofluorescence, the researchers found that higher BMI in women with BRCA mutations was positively correlated with DNA damage in the milk glands.

They determined that the metabolic hormones leptin and insulin, and the hormone oestrogen, which is commonly linked with breast cancer growth, were drivers of this DNA damage.

Furthermore, the scientists found that they could reduce DNA damage in tissue samples in the lab by exposing them to metformin.

This drug, commonly used to manage type 2 diabetes, is also known to suppress the expression of aromatase—an enzyme that is responsible for oestrogen biosynthesis.

“Metformin is an attractive option to study because it has very limited side effects, and we can think about the possibility of using it in a risk reduction setting,” Dr. Brown said. “However, we still need to determine which biomarkers can be used as clear indications of risk reduction in this patient population, beyond closely following people for cancer development.”

In addition to their tissue studies, the researchers assessed mice with BRCA1 mutations to better understand whether an increase in DNA damage is associated with cancerous tumour growth.

The scientists found that obese mice with metabolic dysfunction had higher rates of tumour formation than lean mice. “Not only did obese mice develop tumours earlier, but they also developed tumours at a higher incidence overall by the end of the study,” Dr. Bhardwaj said.

Overall, this study contributes to a better appreciation of the effects of lifestyle, obesity and metabolic health on cancer development in high-risk populations, Dr. Brown said.

The researchers plan to further study the mechanisms that drive DNA damage in the breast tissue of women with BRCA mutations and hope to encourage the clinical study of lifestyle changes or metformin in these patients.

“This line of research may go beyond BRCA1 and BRCA2 mutation carriers,” Dr. Brown said. “It may also have an impact on other hereditary cancers or cancer types.”

Source: Weill Cornell Medicine